Sintx Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Sintx TechnologiesDer Gewinn des Unternehmens wird voraussichtlich um 27.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 12% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 139.4% pro Jahr wachsen.

Wichtige Informationen

-27.1%

Wachstumsrate der Gewinne

139.4%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	22.1%
Wachstumsrate der Einnahmen	12.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	31 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0A8S - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	3	-14	N/A	-11	2
12/31/2024	3	-11	N/A	-9	1
3/31/2024	3	-9	-12	-12	N/A
12/31/2023	3	-8	-15	-14	N/A
9/30/2023	2	-14	-14	-13	N/A
6/30/2023	2	-14	-14	-13	N/A
3/31/2023	2	-14	-13	-12	N/A
12/31/2022	2	-16	-12	-10	N/A
9/30/2022	1	-10	-12	-11	N/A
6/30/2022	1	-10	-14	-11	N/A
3/31/2022	1	-10	-14	-10	N/A
12/31/2021	1	-9	-14	-10	N/A
9/30/2021	1	-9	-13	-10	N/A
6/30/2021	0	-9	-10	-10	N/A
3/31/2021	0	-11	-9	-9	N/A
12/31/2020	1	-17	-9	-9	N/A
9/30/2020	1	-16	-9	-9	N/A
6/30/2020	1	-15	-8	-8	N/A
3/31/2020	1	-14	-8	-8	N/A
12/31/2019	1	-7	-7	-6	N/A
9/30/2019	1	-8	-6	-6	N/A
6/30/2019	0	-15	-7	-7	N/A
3/31/2019	0	-22	-9	-9	N/A
12/31/2018	0	-24	-9	-9	N/A
9/30/2018	N/A	-24	-8	-8	N/A
6/30/2018	-6	-17	-7	-7	N/A
3/31/2018	-3	-9	-5	-5	N/A
12/31/2017	N/A	-6	N/A	-5	N/A
9/30/2017	4	-5	N/A	-6	N/A
6/30/2017	13	-15	N/A	-8	N/A
3/31/2017	14	-18	N/A	-8	N/A
12/31/2016	15	-21	N/A	-7	N/A
9/30/2016	17	-22	N/A	-7	N/A
6/30/2016	18	-21	N/A	-6	N/A
3/31/2016	19	-22	N/A	-8	N/A
12/31/2015	19	-24	N/A	-9	N/A
9/30/2015	20	-31	N/A	-10	N/A
6/30/2015	21	-26	N/A	-11	N/A
3/31/2015	22	-33	N/A	-15	N/A
12/31/2014	23	-33	N/A	-15	N/A
9/30/2014	23	-22	N/A	-16	N/A
6/30/2014	23	-20	N/A	-15	N/A
3/31/2014	23	-9	N/A	-11	N/A
12/31/2013	22	-8	N/A	-10	N/A
9/30/2013	23	-33	N/A	-9	N/A
6/30/2013	23	-34	N/A	-8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0A8S wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0A8S wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0A8S wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0A8SDie Einnahmen des Unternehmens (12% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: 0A8SDie Einnahmen des Unternehmens (12% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0A8S in 3 Jahren voraussichtlich hoch sein wird

Sintx Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

No longer forecast to breakeven

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Sintx Technologies Regains Compliance with Nasdaq Bid Price Requirement

Sintx Technologies Declares 1-for-200 Reverse Stock Split Effective May 28, 2024 to Bring it into Compliance with the Minimum Bid Price Requirements for Maintaining the Listing on the Nasdaq Capital Market

New major risk - Financial position

First quarter 2024 earnings released: US$0.051 loss per share (vs US$0.13 loss in 1Q 2023)

Sintx Technologies Receives New Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

Sintx Technologies, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$2.22 loss per share (vs US$54.67 loss in FY 2022)

Sintx Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $1.030519 million.

Sintx Technologies, Inc. Provides Estimated Revenue for the Fourth Quarter and Full Year Ended December 31, 2023

Third quarter 2023 earnings released: US$0.76 loss per share (vs US$11.02 loss in 3Q 2022)

Sintx Technologies, Inc., Annual General Meeting, Dec 05, 2023

SINTX Technologies Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Sintx Technologies, Inc. Receives Phase II NIH Grant for Silicon Nitride-PEEK 3D Printed Composite Spinal Implants

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.61 loss per share (vs US$10.16 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.13 loss per share (vs US$11.51 loss in 1Q 2022)

Full year 2022 earnings released: US$54.67 loss per share (vs US$35.54 loss in FY 2021)

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $12.04 million.

Insufficient new directors

Sintx Technologies, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sintx Technologies Receives Notice from the Listing Qualifications Staff of Nasdaq

Third quarter 2022 earnings released: US$0.11 loss per share (vs US$0.095 loss in 3Q 2021)

Insufficient new directors

Sintx Technologies, Inc., Annual General Meeting, Dec 15, 2022

Sintx Technologies, Inc. has completed a Composite Units Offering in the amount of $4.7 million.

Sintx Technologies, Inc. Announces New Antibacterial Biomedical Patents and Expansion of Intellectual Property Portfolio

National Institutes of Health Announces Grant to Sintx Technologies for Development of 3D Printed Antimicrobial Trauma Device

Insufficient new directors

Insufficient new directors

Oxford Performance Materials and SINTX Technologies Collaboration Yields Major Breakthrough in Orthopedic & Dental Coatings

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.10 loss per share (vs US$0.089 loss in 2Q 2021)

Insufficient new directors

Sintx Technologies, Inc. (NasdaqCM:SINT) acquired Technology Assessment And Transfer, Inc. for 0.76 million.

Insufficient new directors

Insufficient new directors

No longer forecast to breakeven

Insufficient new directors

Full year 2021 earnings released: US$0.35 loss per share (vs US$1.01 loss in FY 2020)

No longer forecast to breakeven

Insufficient new directors

SINTX Technologies, Inc. Announces New Results on the Development of Manufacturing Technologies to Produce Fabrics Impregnated with SINTX Silicon Nitride, and the Antipathogenic Testing of These Fabrics

SINTX Technologies Receives A Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

No longer forecast to breakeven

Third quarter 2021 earnings released: US$0.095 loss per share (vs US$0.11 loss in 3Q 2020)

Sintx Technologies, Inc. Announces the Sale of First Silicon Nitride Antipathogenic Powder to O2TODAY

First quarter 2021 earnings released: US$0.11 loss per share (vs US$1.35 loss in 1Q 2020)

SINTX Technologies Announces New Product Brand, FleX SN, For Antipathogenic and Biomedical Applications

SINTX Technologies Files Multiple New U.S. and International Patent Applications

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken